Dr. Kemble joined 3-V Biosciences in August 2011 as its Chief Scientific Officer and was promoted to Chief Executive Officer in October 2015. As CSO, Dr. Kemble was responsible for directing the medicinal chemistry, research, translational and CMC groups of 3-V and worked on several programs including the lead product candidate, TVB-2640 for oncology. Prior to joining 3-V, Dr. Kemble was with MedImmune, Inc., a subsidiary of Astra-Zeneca PLC, where he served as Senior Vice President of R&D and Head of Research. During his tenure, Dr. Kemble was responsible a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the successful launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.
Dr. McCulloch (Bill) practiced medicine for seven years in the U.K., including post- graduate training in Internal Medicine, Hematology and Oncology, before joining the international pharmaceutical industry in 1984. Since then, his 31-year career as a senior R&D executive in a variety of large and small companies has afforded him extensive experience in developing and commercializing technologies. His areas of responsibility have included non-clinical and clinical development, regulatory and medical affairs, licensing and sales force training, with a focus in oncology and serious infectious diseases. He has worked for large pharmaceutical companies (Bristol-Myers and Astra), start-up biotechs (U.S. Bioscience, Sparta Pharmaceuticals) and Venture Capital firms (Pappas Ventures). He has undertaken all phases of drug and technology development, and has been directly involved in the U.S. and Europe in filing INDs/CTAs and NDAs/MAAs, with their requisite face-to-face regulatory meetings, securing Orphan Drug status for compounds and obtaining SBIR and other grant funding for his projects. He held the full time position of Chief Medical Officer at Gloucester Pharmaceuticals, Inc., where he led the regulatory strategy and oversaw the conduct of the pivotal trial which led to FDA approval of their HDAC inhibitor, romidepsin (Istodax®) in November 2009 and the subsequent acquisition of the Company by Celgene Corporation in January, 2010. He holds a medical degree (M.B., Ch.B) from the University of Glasgow in Scotland, is a Fellow of the Royal College of Physicians of Glasgow and also a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.
Douglas I. Buckley, Ph.D. joined 3-V Biosciences as Vice President, Biology in June 2012. Dr. Buckley has over 25 years of experience in the biopharmaceutical industry, most recently as Vice President of Biochemistry at Exelixis Inc. where he led research and discovery teams responsible for delivering over thirty IND-ready compounds to Exelixis Clinical Development and to external partnerships. Also during his tenure at Exelixis, he served as Discovery representative to the cabozantinib (XL 184) Global Filing Team with responsibility for coordinating and editing all Discovery Reports included in the NDA filing. Prior to Exelixis, Dr. Buckley was the Department Head of Protein Chemistry and Process Development at Scios, Inc., where he was responsible for process and assay development for two marketed biotherapeutic products (Fiblast® (trafermin) and NATRECOR® (nesiritide)). Doug received his AB in Chemistry and Economics from Bowdoin College, his Ph.D. in Endocrinology from the Hormone Research Laboratory at the University of California, San Francisco, and his post-doctoral training in the Molecular Biology Department at Massachusetts General Hospital and the Department of Genetics at Harvard Medical School.